| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $205,738,079 ) (Continued on the next page) |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA241371 | Investigating apoptotic priming as a determinant of sensitivity to leukemia-directed therapies | 000 | 2 | NIH | 6/30/2022 | $255,045 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA256505 | Mechanistically Dissecting Glycolysis Regulation by Lactate and Its Therapeutic Potential in Cancer | 000 | 2 | NIH | 7/5/2022 | $140,345 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA256351 | Adapting and Testing a Novel Self-Compassion Intervention to Reduce Lung Cancer Stigma | 000 | 2 | NIH | 6/29/2022 | $124,687 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 000 | 2 | NIH | 6/30/2022 | $616,953 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA245636 | Patient-derived organoids reveal rectal cancers develop radiosensitivity | 001 | 2 | NIH | 5/20/2022 | $19,860 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA245636 | Patient-derived organoids reveal rectal cancers develop radiosensitivity | 000 | 2 | NIH | 1/31/2022 | $223,418 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37AI093808 | INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUS | 000 | 13 | NIH | 6/7/2022 | $678,475 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA251591 | Predicting sensitivity and resistance in RET-driven cancers | 000 | 2 | NIH | 4/11/2022 | $396,790 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI150999 | HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | 000 | 2 | NIH | 3/11/2022 | $709,841 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA252633 | Behavioral Activation for Depression in Older Adult Cancer Survivors: Pilot Randomized Control Trial and Implementation Outcomes | 000 | 2 | NIH | 5/13/2022 | $174,699 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AG074004 | Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrum | 000 | 2 | NIH | 6/2/2022 | $1,195,676 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA249666 | HER2-mediated delivery of cytotoxic agents in solid tumors | 000 | 2 | NIH | 4/11/2022 | $576,029 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F32CA260841 | Metabolic determinants of metastatic heterogeneity: quantitative experiments and mathematical models | 000 | 2 | NIH | 7/25/2022 | $73,942 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01HG012103 | Deciphering the Genomics of Gene Network Regulation of T Cell and Fibroblast States in Autoimmune Inflammation | 000 | 2 | NIH | 5/13/2022 | $1,280,000 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01NS118067 | Directing fate, subtype identity and survival in human pluripotent-derived midbrain dopamine neurons | 000 | 2 | NIH | 3/24/2022 | $637,063 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | T32CA254875 | Molecular Imaging in Cancer Biology Training Program | 000 | 2 | NIH | 7/29/2022 | $432,412 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R03CA259863 | Understanding the Guideline-Discordant Use of Bone Modifying Agents in Prostate Cancer | 000 | 2 | NIH | 2/18/2022 | $88,500 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21AI156157 | The mycobiota, bone marrow transplantation, and clinical outcomes | 000 | 2 | NIH | 6/2/2022 | $221,250 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UH3CA257869 | Point of care, real-time urine metabolomics test to diagnose colorectal cancers and polyps in low- and middle-income countries | 001 | 5 | NIH | 5/2/2022 | $0 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA253913 | Comparative Modeling of Effective Policies for Colorectal Cancer Control | 001 | 3 | NIH | 7/19/2022 | $1,133,108 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01HD110120 | Structural and functional principles underlying germline genome transmission | 000 | 1 | NIH | 8/3/2022 | $488,964 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01HD108914 | Essential roles for RNAi/hpRNAs to resolve intragenomic conflicts in the male germline | 000 | 1 | NIH | 5/3/2022 | $599,187 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | RF1AG071805 | [18F]-PU-AD epichaperome PET imaging probe | 000 | 1 | NIH | 6/14/2022 | $3,589,781 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21AG076132 | Molecular mechanisms of age-related lymphatic dysfunction | 000 | 1 | NIH | 7/14/2022 | $265,500 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99AR080207 | Regulation of lupus pathogenesis through modulation of thymic development of pathobiont-specific T cells | 000 | 1 | NIH | 7/14/2022 | $91,908 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U19AI171399 | AI-driven Structure-enabled Antiviral Platform (ASAP) | 001 | 1 | NIH | 6/10/2022 | $11,515 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U19AI171399 | AI-driven Structure-enabled Antiviral Platform (ASAP) | 000 | 1 | NIH | 5/16/2022 | $67,662,387 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 000 | 1 | NIH | 5/6/2022 | $1,284,278 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 001 | 1 | NIH | 5/24/2022 | $0 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258821 | Safer lung cancer radiotherapy delivery using novel artificial intelligence methods | 000 | 1 | NIH | 6/15/2022 | $393,581 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA273224 | Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy | 000 | 1 | NIH | 6/15/2022 | $734,122 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08NS128256 | Defining the role of developmental context in oncohistone-driven gliomagenesis | 000 | 1 | NIH | 8/2/2022 | $195,696 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA266939 | Elucidating determinants of metastasis suppression in pancreatic cancer | 000 | 1 | NIH | 7/8/2022 | $135,348 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31CA275027 | Understanding the divergent functions of mutant p53 | 000 | 1 | NIH | 7/1/2022 | $46,752 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31CA275027 | Understanding the divergent functions of mutant p53 | 001 | 1 | NIH | 7/1/2022 | $0 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21HG012230 | Scalable, quantitative, single-cell CRISPR screens | 000 | 1 | NIH | 8/1/2022 | $265,500 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R03CA259648 | Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer: A Prospective Study | 000 | 1 | NIH | 6/30/2022 | $88,500 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA274059 | Dopamine Metabolism and Nonpharmacologic Insomnia Interventions Among Cancer Survivors | 000 | 1 | NIH | 6/28/2022 | $248,243 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R03CA267333 | Pathway to Equity: Feasibility and Proof of Concept of Meaning-Centered Psychotherapy for Chinese Patients with Advanced Cancer | 000 | 1 | NIH | 7/28/2022 | $88,500 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | P50CA271357 | MATCHES: Making Telehealth Delivery of Cancer Care at Home Effective and Safe | 000 | 1 | NIH | 7/29/2022 | $1,238,984 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA263320 | Discovery and characterization of clinically actionable germline mutations in DNA damage repair (DDR) pathway genes in lung cancer | 000 | 1 | NIH | 6/1/2022 | $719,691 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA259533 | The role of B-cells in the anti-tumor immune response in triple negative breast cancer | 000 | 1 | NIH | 5/9/2022 | $264,185 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00CA259223 | Understanding Ancestral Contribution to Lung Adenocarcinoma | 000 | 2 | NIH | 7/18/2022 | $240,480 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F99CA274656 | Identification of therapeutic targets in clonal hematopoiesis | 000 | 1 | NIH | 7/29/2022 | $48,252 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA266927 | Acupuncture for Cognitive Health in Older Survivors of Prostate Cancer (ACHIEVE) | 000 | 1 | NIH | 7/27/2022 | $248,982 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA264563 | Understanding the Importance of Industry Relationships for Cancer Care Quality, Outcomes, and Costs | 000 | 1 | NIH | 7/27/2022 | $427,793 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01GM144508 | Mechanisms of enhancer-promoter communication, genome organization and transcription control | 000 | 1 | NIH | 7/28/2022 | $484,290 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K00CA245471 | Investigating the Role of Cell Plasticity in Malignant Transformation | 000 | 3 | NIH | 4/12/2022 | $89,230 |
| | 2022 | 2022 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99DK131280 | Developmental lineages and functions of macrophages in white adipose tissue | 000 | 1 | NIH | 5/10/2022 | $90,000 |
|
